A Cross-Sectional Analysis of Syncytiotrophoblast Membrane Extracellular Vesicles 1 **Derived Transcriptomic Biomarkers in Preeclampsia.** 2 Toluwalase AWOYEMI DPhil^{1*}, Wei ZHANG PhD^{1*}, Maryam RAHBAR DPhil¹, Adam 3 CRIBBS PhD², Prasanna LOGENTHIRAN MB;BS¹, Shuhan JIANG DPhil¹, Gavin COLLETT 4 PhD¹, Ana Sofia CERDEIRA PhD¹ & Manu VATISH DPhil^{1,3} 5 6 7 * Equal Contribution 8 1 Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, 9 10 United Kingdom. 2 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, 11 University of Oxford, Oxford, United Kingdom. 12 3. Welcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom. 13 14 15 16 *Corresponding author: Dr Manu Vatish, MBBCh, BA (Hons), DPhil, MA, FMRCOG 17 Manu.vatish@wrh.ox.ac.uk, Phone number- +441865221009, Fax number-01865769141 18 Address: Nuffield Department of Women's and Reproductive Health, University of Oxford, 19 Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom 20

21 Abstract

Background: Preeclampsia (PE) is a pregnancy-specific hypertensive disorder affecting 2-8% of pregnancies worldwide. Biomarker(s) for PE exists, but while these have excellent negative predictive value, their positive predictive value is poor. Extracellular vesicles released by the placenta into the maternal circulation, syncytiotrophoblast membrane extracellular vesicles -STB-EVs- have been identified as being involved in PE with the potential to act as liquid biopsies. **Objective**: To identify differences in STB-EV and placenta transcriptome between PE and normal pregnancy (NP).

Methods: We performed RNA-sequencing (RNA-seq) on placental tissue, medium/large and small STB-EVs from PE (n=6) and NP (n=6), followed by bioinformatic analysis to identify targets that could be used in the future for EV-based diagnostic tests for preeclampsia. Some of the identified biomarkers were validated with real-time polymerase chain reactions.

Results: Our analysis identified and verified the differential expression of FLNB, COL17A1,
SLC45A4, LEP, HTRA4, PAPP-A2, EBI3, HSD17B1, FSTL3, INHBA, SIGLEC6, and CGB3.
Our analysis also identified interesting mechanistic processes via an in-silico prediction of STBEV-based mechanistic pathways.

37 Conclusions: In this study, we identified potential biomarkers and mechanistic gene pathways
38 that may be important in the pathophysiology of PE and could be further explored in future
39 studies.

Funding: This research was funded by the Medical Research Council (MRC Programme Grant
(MR/J0033601) and the Medical & Life Sciences translational fund (BRR00142 HE01.01)

42 Keywords: Transcriptomics, Syncytiotrophoblast membrane extracellular vesicles (STB-EVs),

43 Preeclampsia, Biomarkers, Placenta EVs, mechanisms.

44

45 Introduction

Preeclampsia (PE) is a multisystemic hypertensive disorder that affects approximately 2-8% of 46 pregnancies worldwide (Lisonkova & Joseph, 2013). It is a pregnancy-specific complication which 47 results in hypertension (systolic blood pressure > 140 mmHg / diastolic pressure > 90 mmHg) and 48 49 proteinuria (protein/creatinine ratio of ≥ 30 mg/mmol or more), or evidence of maternal acute kidney injury, liver dysfunction, neurological abnormalities, hemolysis, thrombocytopenia, 50 and/or fetal growth restriction and in severe cases, death(Brown et al., 2018). Preeclampsia in 51 particular, early onset preeclampsia (EOPE) has been referred to as a two-stage process, starting 52 with mal-placentation which results in syncytiotrophoblast stress (stage 1) and ending in 53 maternal end-organ damage (stage 2)(C. W. G. Redman et al., 2022). However, the direct cause 54 of PE (i.e., mechanisms of placental dysfunction) is still under study, with the only available 55 treatment being the delivery of the placenta (C. Redman, 2014). 56

Syncytiotrophoblast membrane extracellular vesicles (STB-EVs) are lipid bilayer spherical 57 structures of placental origin which can be classified based on their size and biogenesis pathways 58 into medium/large and small STB-EVs (Yáñez-Mó et al., 2015). Small STB-EVs are less than or 59 60 equal to 200 nm in size and formed through multivesicular bodies, whereas medium/large EVs are between 201 nm to 1000 nm and released directly through the budding of the plasma 61 62 membrane (Théry et al., 2018). Their cargo consists of surface proteins, encapsulated proteins, and different subclasses of RNAs such as long noncoding RNAs, messenger RNAs, transfer 63 RNAs, and micro RNAs (Colombo et al., 2014), which may be released into target cells through 64 fusion of STB-EVs with distant cells. This ability of STB-EVs further implicates them as 65 potential pathogenic factors in PE. However, the transcriptome of the subtypes of STB-EVs has 66

67 not been thoroughly explored. Previous studies have identified differentially expressed genes (DEGs) from PE placental tissue such as Sialic acid-binding Ig-like lectin 6 (SIGLEC6), 68 Vascular endothelial growth factor receptor 1(VEGFR1), Adrenomedullin (ADM), and 69 Pappalysin-2 (PAPP-A2) (Rumer et al., 2013; Tsai et al., 2011a), Basic Helix-Loop-Helix Family 70 Member E40 (BHLHE40), Divergent-Paired Related Homeobox (DPRX), and HtrA Serine 71 Peptidase 4 (HTRA4) (Ren et al., 2021) compared to normal placental tissue. However, none to 72 the best of our knowledge have explored this in the context of STB-EVs between PE and normal 73 74 pregnancy (NP).

75 We hypothesized that 1) the transcriptome of the placental tissue and STB-EVs are different between PE and NP and 2) analyzing these different sample sub-types would allow for more 76 comprehensive and holistic profiling. We believe this strategy increases the probability of 77 detecting relevant biomarkers and mechanistic pathways in PE. We performed RNA-sequencing 78 (RNA-seq) on placental tissue, medium/large and small STB-EVs from PE and NP. Our analysis 79 revealed novel biomarkers and new insights into possible mechanisms of preeclampsia. This 80 knowledge may help to inform future extracellular vesicle-based diagnostic tests, mechanistic 81 experiments and ultimately, the development of new therapies. 82

83 Methods

84 *Ethics approval and patient information*

We obtained ethical approval from the Central Oxfordshire Research Ethics Committee C (REFS 07/H0607/74 & 07/H0606/148). We obtained written informed consent from pregnant women undergoing elective caesarean sections before labour onset at the Women's Centre, John Radcliffe Hospital, Oxford. Placentas from normal (NP) n=12 and preeclamptic (PE) n=12

89 pregnancies were collected and perfused within ten minutes of delivery. We defined NP as singleton pregnancy with no history of preeclampsia, hypertensive disorders, or other 90 complications in pregnancy. Patients with preeclampsia were defined as the co-occurrence of de 91 92 *novo* hypertension (blood pressure > 140/90 mmHg) and proteinuria (protein/creatinine ratio \geq 30 mg/mmol) and/or evidence of maternal acute kidney injury, liver dysfunction, neurological 93 abnormalities, hemolysis, thrombocytopenia, and/or fetal growth restriction after week twenty of 94 gestation according to the criteria of the International Society for the Study of Hypertension in 95 Pregnancy(Brown et al., 2018). All PE patients used in this study were of early onset PE 96 97 (diagnosed before 34 weeks gestation).

98 Enrichment of STB-EVs by placental dual-lobe perfusion and serial ultracentrifugation

99 We have previously published our protocol of STB-EVs isolation through ex vivo dual lobe placental perfusion (Dragovic et al., 2015). Briefly, we identified a suitable cotyledon (devoid of 100 calcifications, ischemia, or rupture) and cannulated a placental artery and vein perfusing the 101 placenta for three hours at a 4-5 ml/min flow rate to obtain placenta perfusate. The placenta 102 perfusate was centrifuged twice at 1,500 g for ten minutes at 4°C (Beckman Coulter Avanti J-103 20XP centrifuge using a Beckman Coulter JS-5.3 swing-out rotor) to remove cell debris. The 104 supernatant was carefully pooled and spun at 10,000 g (10K) in a swing bucket centrifuge 105 (Beckman L80 ultracentrifuge and Sorvall TST28.39 swing-out rotor) at 4^oC for 30 minutes. 106 The 10K STB-EV pellet was washed with filtered phosphate buffer saline (fPBS) followed by 107 resuspension of the 10K STB-EV pellets in fPBS. An aliquot of the resuspended pellets was 108 analysed to identify and characterise STB-EVs, while the rest were aliquoted to obtain a protein 109 110 concentration around 2-5 µg/µl (measured using a Pierce bicinchoninic acid (BCA) protein assay) and immediately stored at -80°C. The post-10K supernatant was filtered through a 0.22 111

µm Millipore stericup filtration device, then spun at 150,000 g for 2 hours (*Beckman L80 ultracentrifuge with a Sorvall TST28.39 swing-out rotor*) and the 150K STB-EV pellets were washed, resuspended in fPBS and aliquoted like the 10K STB-EV pellets. This working stock was used for subsequent analysis. Our STB-EV enrichment and categorization process has been deposited on EV Track ([http://www.EVTRACK.org], EV-TRACK ID: EV210382) with a score of 78% correlating with excellent enrichment and categorization.

118 Transmission electron microscopy

119 STB-EV pellets were diluted with fPBS to achieve an STB-EV solution with concentrations 120 between 0.1-0.3 μ g/ μ l. Ten microliter of the STB-EV pellet solution was applied to freshly 121 glowing discharged carbon formvar 300 mesh copper grids for two minutes, blotted with filter 122 paper, and stained with 2% uranyl acetate for ten seconds and air-dried. STB-EV pellets on the 123 grid were negatively stained to enhance the contrast between STB-EVs pellets and the 124 background. The grids were imaged using an FEI Tecnai 12 TEM at 120 kV with a Gatan 125 OneView CMOS camera.

126 *Flow Cytometry*

A BD LSRII flow cytometer (BD Biosciences) with a blue, violet, and red laser was used for all
sample analyses. Daily quality control (QC) was run using CS&T beads (BD Biosciences).
Photomultiplier tube (PMT) voltage determined by CS&T run was applied to all fluorescent
detectors with exception for the side scatter (SSC) which was determined by Apogee Mix (1493,
Apogee Flow System, UK). SSC PMT voltage that triggered 0.59 µm silica beads and above was
applied to all 10K STB-EV pellets and analyzed. An SSC threshold of 200 was applied to
remove background noise below 0.59 µm silica beads. A flow rate of 10 µl/min was achieved

134 using the TruCount beads (BD science). For sample staining, 90 ml of 10K STB-EV pellet were incubated with ten ml of Fc receptor blocker (Miltenyl, UK) for 10 minutes at 4^oC and then 135 stained with phycoerythrin (PE) conjugated PLAP (for syncytiotrophoblast origin), PE Vio770 136 conjugated anti classical HLA class I and II (to exclude co-isolated non-placenta EVs and white 137 blood cell (WBC) EV co-isolation), Pacific blue conjugated CD41 (to identify co-isolated 138 platelet EVs) and CD235a (to identify co-isolated red blood cell (RBC) EVs) for ten minutes at 139 room temperature in the dark. Stained samples were transferred to an Ultra free 0.2 µm filter unit 140 (Millipore) and centrifuged at 800 g for three minutes to remove unbound antibodies and EVs 141 smaller than the filter pore size. Ninety microliters of fPBS were used to recover 10K STB-EVs 142 retained on the filter membrane. Recovered 10K STB-EVs were further stained with BODIPY 143 FL N-(2-aminoethyl)-maleimide [505/513 nm] (Molecular Probes) at a final concentration of 0.5 144 nM in the dark at room temperature for ten minutes before samples were diluted to 500 ml and 145 analyzed on the flow cytometer to check for events rate. When necessary, dilutions were made to 146 achieve an events rate of \leq 400 count/second and to reduce swarming. 10K STB-EV pellets were 147 analyzed at 10 μ l/minute for ten minutes and a total of 100 μ l diluted samples was analyzed for 148 each sample. Fluorescence minus one (FMO-1) for each fluorochrome and stained samples re-149 acquired after 2% Nonidet P-40 (NP-40) (Sigma) treatment were used as controls. Data and 150 figures generated were generated with the Flowjo software version 10 (Tree Star Inc., Ashland, 151 OR). 152

153 Nanoparticle Tracking Analysis

We further characterised the 10K and 150K STB-EV pellets by nanoparticle tracking analysis [(NTA) NanoSight NS500 instrument equipped with a 405 nm laser (Malvern UK), sCMOS camera and NTA software version 2.3, Build 0033 (Malvern UK)]. Before sample analysis,

157 instrument performance was checked with silica 100 nm microspheres (Polysciences, Inc.). The 10K and 150K STB-EV pellets were individually diluted in fPBS to a range of 1/100,000. The 158 samples were automatically injected into the sample chamber with a 1 ml syringe with the 159 160 following script used for EV measurements: prime, delay 5, capture 60, repeat 4. Images of the analyzed samples were captured on camera at level 12 (Camera shutter speed; 15 milliseconds 161 and Camera gain; 350) and NTA post-acquisition settings were optimized and kept constant 162 between samples. Each video recording was analyzed to infer STB-EVs size and concentration 163 164 profile.

165 Western Blot Analysis

We performed western blots on placental lysates (PL) and STB-EVs to further characterise and immune-phenotype. All STB-EVs pellets were probed with PLAP (for syncytiotrophoblast origin), CD63 and ALIX (to confirm the presence of extracellular vesicles), and Cytochrome C (as a negative EV marker) as recommended by the international society for extracellular vesicles (ISEV) (Théry et al., 2018). Following characterization and identification of extracellular vesicles in 10K and 150K STB-EV pellets, we renamed them to medium/large (m/l) and small (s) STB-EVs respectively.

173 RNA-Sequencing Library Preparation and Sequencing

For sequencing, RNA extraction and sample preparations were performed for placenta tissue (discovery cohort-6 NP, 6 PE) with the RNeasy mini kit and STB-EVs (6 NP, 6 PE) with the miRCURYTM RNA isolation kit for biofluids (Exiqon Services, Denmark) based on manufacturer's protocol. The samples were sent to the Wellcome Centre for Human Genetics

178 (WCHG) for sequencing using standard Illumina protocol. Details can be found in the179 supplementary material.

180 Bioinformatics and Statistical Analysis of Messenger RNA sequences

We performed bioinformatics analysis on Galaxy (https://usegalaxy.org/). We used FastQC 181 (Galaxy Version 0.72+galaxy1) to obtain overall OC metrics and MultiOC (Galaxy Version 182 1.9+galaxy1) to amalgamate the QC metrics before and after trimming of adapters [trimmomatic 183 (Galaxy Version 0.38.0)]. Alignment was referenced to reference Homo Sapiens build 38 (hg38) 184 genomes obtained from Ensembl with HISAT 2 (Galaxy Version 2.2.1+galaxy0). For each 185 sample, *featureCounts* (Galaxy Version 2.0.1+galaxy1) was used to quantify genes based on 186 reads that mapped to the provided hg38 genome. A count matrix was generated with the Column 187 Join on Collection (Galaxy Version 0.0.3) tool. Differential expression analysis was done with 188 the DESeq2 package (v.1.32.0 in R v.4.0.5). The reported p-values were adjusted for multiple 189 testing using Benjamin Hochberg correction reported as false-discovery rate. An adjusted p-190 191 value less than 0.05 was taken as significant. Functional annotation was performed with ClusterProfiler (for Gene Ontology [GO] and KEGG) and Signalling pathway impact analysis 192 (SPIA) with our transcriptome set as the background. The raw fastQ files and processed file 193 have been deposited in NCBI and can be accessed with the following ID: GSE190973. 194

195 Criteria for genes selection for validation

We chose a select group of DCGs between NP and PE to validate based on 1) fold change (genes with a high fold change [log FC \ge (±)1] and adjusted P Value \le 10⁻⁵), 2) presence in at least two of the three sample types (placenta lysate, m/l STB-EVs, and sSTB-EVs), 3) placenta specificity or enrichment and, 4) previous molecules investigated by the group. Based on expression data at

200 the protein and RNA level from the human protein atlas (Uhlen et al., 2017), genes are said to be placenta specific if they are expressed only in the placenta, while genes are placenta enriched if 201 the placenta is one of the five with the highest expression. 202

203

Quantitative polymerase chain reaction (qPCR) for mRNA validation

Following standard protocol, the high-capacity cDNA Reverse transcription kit (Applied 204 Biosystems, USA) was used for reverse transcription of the validation cohort (n = 6 [PE], 6 205 [NP]). Quantitative polymerase chain reaction was performed on Quant StudioTM 3 real-time 206 PCR systems, (Quant StudioTM Design and analysis software), MicroAmpTM Optical 96-well 207 reaction plate (N8010560) and optical adhesive film kit (4313663), with the hydrolysis probe-208 based Taqman (R) gene expression assay (Applied Biosystems, USA). The following settings 209 were used: hold 50°C for 2 minutes, hold at 95°C for 20 seconds, followed by forty 95°C for 1 210 second and 60°C for 20 seconds. Cq values were generated automatically by the Quant Studio 211 Design and Analysis desktop software. The geometric mean of YWHAZ and SDHA were used as 212 213 the internal reference genes for the normalization of all qPCR data. We analyzed the qPCR data and calculated fold changes using the $2^{-\Delta\Delta Ct}$ method (Livak & Schmittgen, 2001). Data was 214 expressed as fold change, and standard error is denoted as error bars with GraphPad Prism 215 software (version 9). Statistical testing was made on the Δ Ct values using a one-tailed Student t-216 *test,* and significance was set at P < 0.05. All gene expression assays, their corresponding assay 217 218 IDs, and all other details used in this study are listed in supplementary material.

219

220

- **Results**

Patient demographics and clinical characteristics

There were no significant differences in maternal age, body mass index, and the gender of the neonates (Table 1). The average systolic (178.83 mmHg) and diastolic (109.17 mmHg) blood pressure was significantly higher among the PE cohort (P<0.001). Likewise, there was a significant difference in proteinuria (PE = 2.58; NP = 0 pluses on urine dipstick; P < 0.001) and gestational age at delivery (PE = 32.00 weeks gestation, NP = 39.17 weeks gestation P = 0.001) in PE compared to NP. Finally, PE neonates were more likely to be growth restricted (100%; 0% P = 0.004) with an average birth weight of 1515.83 g compared to 3912.50 g in normal neonates (P < 0.001).

242

- 243
- 244
- **Table 1.** General characteristics of the transcriptomic cohort study population

Characteristics	Normal Pregnancy	Preeclampsia	P Value
Sample size	6	6	
Maternal age years (mean			
(SD))	34.50 (5.39)	36.33 (4.13)	0.524
Body mass index kg/m ⁻²			
(mean (SD))	29.92(9.10)	31.25 (11.12)	0.825
Systolic blood pressure			
mmHg (mean (SD))	129.50 (4.93)	178.83 (12.56)	<0.001
Diastolic blood pressure			
mmHg (mean (SD))	67.00 (6.20)	109.17 (9.85)	<0.001
Proteinuria plus(es)			
(mean (SD))	0	2.58 (1.20)	<0.001
Gestational age at			
delivery in weeks (mean			
(SD))	39.17 (0.98)	32.00 (3.52)	0.001
Birth weight (grams)			
(mean (SD))	3912.50 (730.40)	1515.83 (600.57)	<0.001
Intrauterine growth	0 (0)	6(100)	0.004

	restriction (IUGR) = Yes			
	(%)-			
	Male new-born gender (%)	2 (33.3)	2 (33.3)	1.000
246	*Sample size for the transcriptom	nics cohort (PL [NP=	6, PE=6], and STB-EVs	s [NP=6, PE=6). q
247	PCR confirmation for PL was per	rformed on the same	cohort (PL [NP=6, PE=	6]) while STB-EV
248	qPCR validation was performed of	on a different cohort	(NP=6, PE=6)– those pa	atient
249	characteristics in supplementary of	data.		

250

251 Characterization of STB-EVs by TEM, NTA, flow cytometry, and WB

252 We characterized our sample preparations with transmission electron microscopy (TEM), nanotracking analysis (NTA), flow cytometry (FC), and western blot (WB) after the isolation 253 and enrichment of STB-EVs. TEM (Figure 1A) showed the typical cup-shaped morphology of 254 extracellular vesicles. In particular, the 10K STB-EV pellet (Figures 1A2, 1A5 and 1A8) showed 255 a size heterogeneity characteristic of m/ISTB-EVs (221 to 1000 nm) and the 150K STB-EV 256 pellet (Figures 1A3, 1A6, and 1A9) showed a homogeneous EVs size profile (less than or equal 257 to 220 nm). This finding was also replicated by NTA (Figure 1C). The 10K STB-EV (Figure 258 1C1) pellets had a modal size of 479.4 ± 145.6 nm, while the 150K STB-EV (Figure 1C2) pellets 259 260 had a smaller modal size (205.8 ± 67.7 nm). The post 10K and post 150K pellets are hereafter renamed m/ISTB-EVs and sSTB-EVs, respectively. WB (Figure 1B) detected PLAP (66 KDa), 261 tetraspanins (CD63 [30-65 KDa]), and endosomal trafficking proteins (ALIX [95 KDa]). The 262 263 non-EV marker cytochrome C (12 KDa) was detected in the placenta lysate but not the STB-EV fractions. Notably, TSG101 and ALIX were more prominent in the sSTB-EV fractions than the 264 m/ISTB-EV fractions and placenta lysate. 265

266	Flow cytometry (Figure S1) was only performed on the m/ISTB-EVs due to the size detection
267	limit of flow cytometry which does not permit interrogation of small STB-EVs. We found 85 \pm
268	8.3 % (Figure S1C) of qualified events were negative for the following lineage markers (CD41
269	[platelets] and CD235a [red blood cells], and HLA-I and II [white blood cells]). 95 \pm 1.2 % of
270	the EVs negative for non-placental markers (listed above) were BODIPY FL N-(2-aminoethyl)-
271	maleimide (bioM) and placental alkaline phosphatase (PLAP) double-positive (Figure S1D).
272	PLAP is a specific marker of syncytiotrophoblast, and bioM a marker of EVs, so this analysis
273	confirmed that most of the post 10K samples, within the detection size range, were of placental
274	origin. NP-40 (detergent) treatment confirmed that our samples were largely vesicular since only
275	$0.1 \pm 0.12\%$ BODIPY FL N-(2-aminoethyl)-maleimide and PLAP double-positive events were
276	detected (a reduction of 99%) after treatment with detergent (Figure S1E).
277	
278	
279	
280	
281	
282	
283	
284	
285	
286	



288

Figure 1. STB-EV characterization. Figure A displays representative transmission electron microscopy (TEM) images with wide view of samples (A1, A4, and A7), medium/large STB-EVs (A2, A5, and A8) displaying heterogeneity of vesicle sizes, and small STB-EVs (A3, A6, and A9) displaying typical cup shaped morphology. Figure 1B is a western blot of placenta homogenate (PL), m/ISTB-EVs (10K) and sSTB-EVs (150K) showing positivity for PLAP in all samples confirming placental origin. sSTB-EVs express enhanced levels of ALIX and CD63 which are known exosomal markers. The absence of cytochrome C in the STB-EV population

296	confirms no contamination. Figure 1C shows the NTA results of m/l STB-EVs (C1) which show
297	a broad size distribution and sSTB-EVs (C2) which display a more homogeneous size.
298	
299	Differentially carried genes (DCGs) in placenta homogenate, m/lSTB-EVs and sSTB-EVs
300	between PE and NP
301	Transcriptomic analysis was performed on the discovery cohort (n=6 [PE], 6 [NP]). Comparison
302	between PE and NP placental tissue revealed 580 upregulated and 563 downregulated (total)
303	genes (adjusted P value of $< 10^{-5}$ [Figures S3]) while in m/ISTB-EVs 1,128 were upregulated
304	and 833 were downregulated (adjusted P value of $< 10^{-5}$ [Figures 2]). In sSTB-EVs, 232 were
305	upregulated, and 106 were downregulated (adjusted P value of $< 10^{-5}$ [Figures S4]). We noted
306	25 downregulated genes, and 120 upregulated genes were common to all three sample types.
307	
308	
309	
310	
311	
312	
313	



317



318

319

Figure 2. Representative volcano plot showing differentially expressed genes in medium/large STB-EVs. The most significantly upregulated genes are displayed in red on the right while the most significantly downregulated genes are displayed in red on the left. Volcano plots for placenta and small STV-EVs are in the supplemental data. -Log₁₀P refers to the negative logarithm of the adjusted P Value.

325

327

328

329 Quantitative PCR (qPCR) Validation of selected Genes

Ouantitative PCR was performed on a different subset of STB-EVs, the validation cohort (n=6 330 [PE], 6 [NP]). As earlier discussed in the methods section, we identified the DCGs that were 331 common between all three sample types (common DCGs) and of those, we selected a subset that 332 were placenta enriched or specific based the criteria mentioned in the methods section. We 333 selected HTRA4, PAPP-A2, EBI3, HSD17B1, FSTL3, INHBA, SIGLEC6, and CGB3. We 334 performed qPCR analysis of these genes in both m/ISTB-EVs and sSTB-EVs. As a proof of 335 concept, four of these genes known to be altered in PE in placental tissues (LEP, COL17A1, 336 SLC45A4, and FLNB) were analyzed in the placenta and we confirmed that these genes were 337 indeed significantly altered in PE (Figure 3). We next moved on to the species of interest and 338 showed that in the m/l STB-EVs (Figures 3 and 4), LEP, SIGLEC6, FLNB, COL17A1, SLC45A4, 339 FSTL3, and HTRA4 were significantly different in PE compared to NP. 340

In sSTB-EVs, (Figure 3 and 4) all the selected genes (except for *SLC45A4 and HSD17B1*) were significantly different. Across the three sample types, *LEP*, *COL17A1*, and *FLNB* were all significantly different between PE and NP while *SIGLEC6*, *FSTL3*, and *HTRA4* were significantly different in both m/l and sSTB-EVs.



Figure 3. Quantitative PCR validation of selected differentially expressed/carried genes leptin (LEP), collagen type XVII alpha 1 chain (COL17A1), solute carrier family 45 member 4 (SLC45A4), filamin B (FLNB) and endoglin (ENG) in the placenta, medium/large STB-EVs and small STB-EVs. Data is visualized as mean fold change and error bars represent standard error. *=P < 0.05, **=P < 0.01, ***=P < 0.001, and ****=P < 0.0001. Sample size (n) = 6(NP) and 6(PE)

351



353 Figure 4. Quantitative PCR validation of placenta specific genes; pappalysin 2 (PAPP-A2), 354 inhibin subunit beta A (INHBA), sialic acid binding Ig like lectin 6 (SIGLEC6), HtrA serine peptidase 4 (HTRA4), Epstein-Barr virus-induced 3 (EBI3), follistatin like 3 (FSTL3), 355 hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1), chorionic gonadotropin 3 (CGB3) and 356 357 age-related macular degeneration (ARMS2) in medium/large STB-EVs and small STB-EVs based on qPCR. Data is visualized as mean fold change, and error bars represent standard error. 358 *=P < 0.05, **=P < 0.01, ***=P < 0.001, and ****=P < 0.0001. Sample size (n) = 4(NP) and 359 4(PE). 360

361

362

363

365 Functional enrichment analysis and Signalling pathway impact analysis (SPIA) of 366 differentially expressed genes (DEGs) in preeclampsia (PE)

367 To understand the role of these genes and perhaps STB-EVs in the pathophysiology of 368 preeclampsia, we performed a functional enrichment analysis (with overrepresentation analysis) on the list of DCGs (between NP and PE) for placenta tissue, m/ISTB-EVs, and sSTB-EVs and 369 370 identified functional processes that overlap among the three sample subtypes. There were 32 similar biological processes between the placenta and sSTB-EVs (See full list Table S4). One 371 372 biological process was similar between the placenta and m/ISTB-EVs (platelet degranulation), 373 two biological processes; cell adhesion molecule and integrin-binding common to both placenta and sSTB-EVs and no biological process was common to all sample subtypes. 374

When analysing KEGG pathways, *focal adhesion* was overrepresented among all three sample types while the *HIF-1 signalling pathway, proteoglycans in cancer, central carbon metabolism in cancer* were overrepresented in both placental tissue and sSTB-EVs.

378 Signalling pathway impact analysis of the DEGs in placental tissue homogenate showed neuroactive ligand-receptor interaction, ECM-receptor interaction, focal adhesion, amoebiasis, 379 and gap junction as the most overrepresented. Of these five, all were inhibited except the 380 neuroactive ligand-receptor interaction, which was activated. In contrast, the same analysis on 381 m/ISTB-EVs revealed two significantly dysregulated pathways, focal adhesion, and cytokine-382 383 cytokine interaction pathways, both of which were activated. Similarly, in sSTB-EVs, three pathways *adipocytokine*, *focal adhesion*, and *type II DM* were significantly activated. Among all 384 three sample types, *focal adhesion* was common to all. 385

387 Discussion

388 Principal findings

In recent years, extracellular vesicles (EVs) have gained interest, particularly their role in the context of PE, their potential to affect functional changes in organs distant from the placenta, and their ability to act as circulating liquid biopsies, revealing data about the donor cells in real-time. Our analysis found the STB-EV transcriptomic signature in PE to be different than in NP. We identified and validated STB-EV mRNAs—;FLNB, COL17A1, SLC45A4, LEP, HTRA4, PAPP-A2, EBI3, HSD17B1, FSTL3, INHBA, SIGLEC6, and CGB3. Exploration of these differentially abundant mRNAs as circulating biomarkers may help early identification of PE.

Results in the context of what is known.

Some of the findings of this study such as FLT1, LEP (Tsai et al., 2011b), ENG, PAPP-A2 (Guo 397 et al., 2021), FSTL3, PRG2 (Gormley et al., 2017), INHBA (Brew et al., 2016), have been well 398 399 described in the placenta but not previously described in STB-EVs. These STB-EV associated mRNA may account for some circulating mRNA such as PAPP-A2, LEP, and HTRA4 (Munchel 400 et al., 2020) detected in increased amounts in PE patients. We opted to validate the following 401 genes: FLNB, COL17A1, SLC45A4, LEP, ENG, HTRA4, PAPP-A2, EBI3, HSD17B1, ARMS2, 402 FSTL3, INHBA, SIGLEC6, and CGB3 since these fulfilled the criteria for biomarkers as outlined. 403 We discovered that on m/ISTB-EVs, FLNB, COL17A1, SLC45A4, LEP, FSTL3, HTRA4 and 404 SIGLEC6 were significantly differentially expressed between PE and normal. Equally 405 interestingly, in sSTB-EVs we found that except for HSD17B1, all the other genes were 406 407 differentially carried between PE and normal.

LEP was the most significantly elevated gene in placental tissue, m/ISTB-EV and sSTB-EVs. The discovery of LEP in STB-EVs is novel. The role of its protein, not its mRNA, as a potential biomarker has been suggested previously(Taylor et al., 2015). LEP plays a role in endocrine functions, reproduction, immune function and is produced by the placenta, aiding implantation, and regulating placental growth (Castellucci et al., 2000). The dysregulation of leptin has been linked to pregnancy complications with higher circulating protein levels associated with PE (Masuyama et al., 2010).

Similarly, we found significantly elevated COL17A1 in the placenta, m/ISTB-EV and sSTB-EV. COL17A1 is a collagen transmembrane protein involved in extracellular matrix receptor interactions. It has been identified, through mass spectrometry, to be differentially expressed in urine samples from PE. In contrast, we found that SLC45A4 mRNA was significantly downregulated in both types of vesicles. *SLC45A4* protein is involved in promoting glycolysis and autophagy prevention (Chen et al., 2021), two processes found to be abnormal in PE (Bloxam et al., 1987).

422 FLNB is an essential cytoskeletal protein critical in endothelial cell motility and that has been previously reported to be downregulated in PE placentae at the mRNA and protein level(Tejera 423 et al., 2013; Wei et al., 2019). This contrasts with our study which showed that FLNB gene was 424 significantly elevated in placenta and in m/ISTB-EV and sSTB-EV. It is difficult to identify the 425 exact reason for the variance, but the choice of housekeeping gene may be a possible 426 explanation. Wei et al used β actin which has been observed to be variable and a potential 427 confounder in other disease states or experimental conditions (Glare et al., 2002). We used the 428 429 geometric mean of YWHAZ and SDHA; both previously shown to be stably expressed(Meller et al., 2005) 430

431 Our analysis also showed that SIGLEC6 was differentially present in both subset of STB-EVs. Our group had previously reported the presence in higher concentration in PE placentas 432 compared to NP(Awoyemi et al., 2020). SIGLEC6 regulates immune cell by interacting with 433 sialic acid on these cells and inhibiting cellular activation and clonal expansion (Zhang et al., 434 2007) through cytosolic tyrosine-based regulatory motif (Brinkman-Van der Linden et al., 2007). 435 FSTL3 glycoprotein is localized to the decidua and has been well documented to be present in 436 abundance in PE placenta and plasma samples. (Xie et al., 2018)[,] (Founds et al., 2015). Our 437 analysis demonstrates that this elevation is also mirrored at the mRNA level in STB-EVs. 438 HTRA4 was found to be differentially carried in PE STB-EVs in our analysis. HTRA4 is a 439 placental-specific serine protease that inhibits cell cycle progression and cell differentiation to 440 endothelial cells (Wang et al., 2019). HTRA4 may be responsible for endothelial cell 441 dysregulation by disrupting endothelial tube formation and increasing endothelial cell 442 permeability (Singh et al., 2015). 443

We also attempted to provide mechanistic insights into the roles of these differentially carried 444 genes in the pathogenesis of PE. We identified HIF 1 pathway, blood vessel development (Guo 445 et al., 2021), adipocyte regulation, retinoic acid regulation, hypoxic signaling, associated 446 447 cytokine pathways (Benny et al., 2020), PI3/Akt signaling, and pathways in cancer (Li & Fang, 2019) as pathways that are potentially contributory. We also found several less well characterized 448 and potentially relevant pathways such as processes involved with protein catabolism and 449 degradation, insulin and other growth factor receptor signaling pathways, nervous system 450 development, ion channel activities, transcription repression, among others. Interestingly, the 451 signalling pathway impact analysis found that the *focal adhesion pathway* was inhibited in the 452 placenta but activated in both STB-EV subtypes. Cvtokine-cytokine interactions were activated 453

in m/ISTB-EVs, while *type II DM* (diabetes mellitus) and *adipocytokine* pathways were activated
in sSTB-EVs. The risk of PE is known to be increased by 2-4-fold among type II DM patients,
and women with a history of PE are more likely to develop type II DM later in life(Weissgerber &
Mudd, 2015). None of the patients used in this study had been diagnosed with diabetes mellitus. If
they had, it may have explained why this pathway was activated in our analysis. It may be
interesting to explore, in the future, if sSTB-EVs play a role in this association or if this

Finally, *focal adhesion* is a critical step in cell and extracellular matrix (ECM) interaction and perhaps interactions between the trophoblast and the ECM and is crucial in trophoblastic invasion and PE (He et al., 2015). In our analysis, we found this pathway to be inhibited in the placenta but activated in m/l and sSTB-EVs. It is reasonable to assume that the differences in the GO terms and pathways among all sample types may portray a difference in roles between the placenta, M/L STB-EVs, and S STB-EVs in the pathogenesis of the disease. However, we believe these differences may be best explored in futured studies.

468 Ideas and Speculations

Our findings have identified several potential STB-EV mRNA biomarkers which require external validation especially in biofluids like plasma, serum, or urine. The prospect of a qPCR biomarker panel is interesting as a qPCR panel should be cheaper and easier to implement than a quantitative protein assay. Such tests are easily scalable and if validated might even be adaptable to low-income resource settings using Loop-Mediated Isothermal Amplification (LAMP) PCR, a PCR technique than can be performed at room temperature. Since transcriptome level alterations precedes proteome level alterations, mRNA based biomarkers may theoretically be better at

ascertaining the risk of developing preeclampsia before the development of clinical symptomsthan standard of care.

478 Strengths and limitations

Our study is not without limitations that should be considered while interpreting the results. First, 479 our sample size is relatively small and thus no predictive analysis could be conducted. Secondly, 480 it is difficult to find a gestational age matched control for PE, particularly the early onset 481 phenotype (< 34 weeks). Therefore, we used term (37 to 41^{+6} weeks) controls. This is a standard 482 approach for all scientists working on PE placentas. Lastly, like most studies on PE, the samples 483 are from deliveries. It is possible these biomarkers represent differences observed at end-stage 484 disease and would require further research to translate these markers to early developmental 485 stages. Notwithstanding, this study has numerous positives, particularly our ability to utilize a 486 comprehensive analysis of three linked sample types from the same patient. This has permitted 487 the dissection of differences between the tissue and the EVs and identification of some 488 potentially exciting pathways which may form the basis of further research. 489

490 Conclusions

Despite intensive efforts, the pathophysiology of preeclampsia (PE) has still not been completely unraveled. In this study, we identified potential mRNA biomarkers and mechanistic gene pathways that may be important in the pathophysiology of PE and could be further explored in future studies. The potential utilization of STB-EVs based mRNA as circulating biomarkers with real time placental and fetal information may be important in early PE diagnosis and mechanism.

496 Acknowledgments

497 We acknowledge the support of the National Institute of Health Research Clinical Research

498 Network Fenella Roseman & Lotoyah Carty research for assistance in patient recruitment.

499

500 **Competing interests:**

501 The authors declare no competing interests.

502 **References**

503	Awoyemi, T., Tannetta, D., Zhang, W., Kandzija, N., Motta-Mejia, C., Fischer, R., Heilig, R., Raiss, S.,
504	Redman, C., & Vatish, M. (2020). Glycosylated Siglec-6 expression in syncytiotrophoblast-derived
505	extracellular vesicles from preeclampsia placentas. <i>Biochemical and Biophysical Research</i>
506	Communications, <i>533</i> (4), 838–844. https://doi.org/10.1016/j.bbrc.2020.09.081
507 508 509	Benny, P. A., Alakwaa, F. M., Schlueter, R. J., Lassiter, C. B., & Garmire, L. X. (2020). A review of omics approaches to study preeclampsia. <i>Placenta, 92</i> , 17–27. https://doi.org/10.1016/j.placenta.2020.01.008
510 511 512	Bloxam, D. L., Bullen, B. E., Walters, B. N. J., & Lao, T. T. (1987). Placental glycolysis and energy metabolism in preeclampsia. <i>American Journal of Obstetrics and Gynecology, 157</i> (1), 97. https://doi.org/10.1016/S0002-9378(87)80354-X
513 514 515	Brew, O., Sullivan, M. H. F., & Woodman, A. (2016). Comparison of normal and pre-eclamptic placental gene expression: A systematic review with meta-analysis. <i>PLoS ONE, 11</i> (8), 1–20. https://doi.org/10.1371/journal.pone.0161504
516	Brinkman-Van der Linden, E. C., Hurtado-Ziola, N., Hayakawa, T., Wiggleton, L., Benirschke, K., Varki, A.,
517	& Varki, N. (2007). Human-specific expression of Siglec-6 in the placenta. <i>Glycobiology, 17</i> (9), 922–
518	931. https://doi.org/10.1093/glycob/cwm065
519 520 521 522	 Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren, C. E., Adoyi, G., & Ishaku, S. (2018). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. <i>Hypertension</i>, 72(1), 24–43. https://doi.org/10.1161/HYPERTENSIONAHA.117.10803
523	Castellucci, M., De Matteis, R., Meisser, A., Cancello, R., Monsurrò, V., Islami, D., Sarzani, R., Marzioni,
524	D., Cinti, S., & Bischof, P. (2000). Leptin modulates extracellular matrix molecules and
525	metalloproteinases: Possible implications for trophoblast invasion. <i>Molecular Human</i>
526	<i>Reproduction</i> , <i>6</i> (10), 951–958. https://doi.org/10.1093/molehr/6.10.951
527	Chen, W., Huang, F., Huang, J., Li, Y., Peng, J., Zhuang, Y., Huang, X., Lu, L., Zhu, Z., & Zhang, S. (2021).
528	SLC45A4 promotes glycolysis and prevents AMPK/ULK1-induced autophagy in TP53 mutant

529 pancreatic ductal adenocarcinoma. *Journal of Gene Medicine*, 23(9), 1–12.

- 530 https://doi.org/10.1002/jgm.3364
- Colombo, M., Raposo, G., & Théry, C. (2014). Biogenesis, secretion, and intercellular interactions of
 exosomes and other extracellular vesicles. *Annual Review of Cell and Developmental Biology*, *30*,
 255–289. https://doi.org/10.1146/annurev-cellbio-101512-122326
- Dragovic, R. A., Collett, G. P., Hole, P., Ferguson, D. J. P., Redman, C. W., Sargent, I. L., & Tannetta, D. S.
 (2015). Isolation of syncytiotrophoblast microvesicles and exosomes and their characterisation by
 multicolour flow cytometry and fluorescence Nanoparticle Tracking Analysis. *Methods*, *87*, 64–74.
- 537 https://doi.org/10.1016/j.ymeth.2015.03.028
- Founds, S. A., Ren, D., Roberts, J. M., Jeyabalan, A., & Powers, R. W. (2015). Follistatin-like 3 across
 gestation in preeclampsia and uncomplicated pregnancies among lean and obese women.
 Reproductive Sciences, 22(4). https://doi.org/10.1177/1933719114529372
- Glare, E. M., Divjak, M., Bailey, M. J., & Walters, E. H. (2002). β-actin and GAPDH housekeeping gene
 expression in asthmatic airways is variable and not suitable for normalising mRNA levels. *Thorax77*,
 57(9), 765–770. https://doi.org/10.1136/thorax.57.9.765
- Gormley, M., Ona, K., Kapidzic, M., Garrido-Gomez, T., Zdravkovic, T., & Fisher, S. J. (2017).
 Preeclampsia: novel insights from global RNA profiling of trophoblast subpopulations. *American Journal of Obstetrics and Gynecology*, *217*(2), 1–17. https://doi.org/10.1016/j.ajog.2017.03.017
- Guo, F., Zhang, B., Yang, H., Fu, Y., Wang, Y., Huang, J., Cheng, M., Li, X., Shen, Z., Li, L., He, P., Xiang, A.
 P., Wang, S., & Zhang, H. (2021). Systemic transcriptome comparison between early- And lateonset pre-eclampsia shows distinct pathology and novel biomarkers. *Cell Proliferation*, *54*(2), 1–15.
 https://doi.org/10.1111/cpr.12968
- He, P., Shao, D., Ye, M., & Zhang, G. (2015). Analysis of gene expression identifies candidate markers and
 pathways in pre-eclampsia. *Journal of Obstetrics and Gynaecology*, *35*(6), 578–584.
 https://doi.org/10.3109/01443615.2014.990430
- Li, X., & Fang, Y. (2019). Bioinformatics identification of potential genes and pathways in preeclampsia
 based on functional gene set enrichment analyses. *Experimental and Therapeutic Medicine*, *18*(3),
 1837–1844. https://doi.org/10.3892/etm.2019.7749
- Lisonkova, S., & Joseph, K. S. (2013). Incidence of preeclampsia: risk factors and outcomes associated
 with early- versus late-onset disease. *Am J Obstet Gynecol, 209*(6), 544 e1-544 e12.
 https://doi.org/10.1016/j.ajog.2013.08.019
- Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time
 quantitative PCR and the 2-ΔΔCT method. *Methods*, 25(4), 402–408.
 https://doi.org/10.1006/meth.2001.1262
- 563 Masuyama, H., Segawa, T., Sumida, Y., Masumoto, A., Inoue, S., Akahori, Y., & Hiramatsu, Y. (2010).
- 564 Different profiles of circulating angiogenic factors and adipocytokines between early- and late-
- 565 onset pre-eclampsia. BJOG: An International Journal of Obstetrics and Gynaecology, 117(3), 314–
- 566 320. https://doi.org/10.1111/j.1471-0528.2009.02453.x

567 Meller, M., Vadachkoira, S., Luthy, D. A., & Williams, M. A. (2005). Evaluation of housekeeping genes in

- 568 placental comparative expression studies. *Placenta*, *26*(8–9), 601–607.
- 569 https://doi.org/10.1016/J.PLACENTA.2004.09.009
- 570 Munchel, S., Rohrback, S., Randise-Hinchliff, C., Kinnings, S., Deshmukh, S., Alla, N., Tan, C., Kia, A.,
- 571 Greene, G., Leety, L., Rhoa, M., Yeats, S., Saul, M., Chou, J., Bianco, K., O'Shea, K., Bujold, E.,
- 572 Norwitz, E., Wapner, R., ... Kaper, F. (2020). Circulating transcripts in maternal blood reflect a
- 573 molecular signature of early-onset preeclampsia. *Science Translational Medicine*, *12*(550).
- 574 https://doi.org/10.1126/SCITRANSLMED.AAZ0131
- Redman, C. (2014). Pre-eclampsia: A complex and variable disease. *Pregnancy Hypertens*, 4(3), 241–242.
 https://doi.org/10.1016/j.preghy.2014.04.009
- Redman, C. W. G., Staff, A. C., & Roberts, J. M. (2022). Syncytiotrophoblast stress in preeclampsia: the
 convergence point for multiple pathways. *American Journal of Obstetrics and Gynecology*, 226(2S),
 S907–S927. https://doi.org/10.1016/J.AJOG.2020.09.047
- Ren, Z., Gao, Y., Gao, Y., Liang, G., Chen, Q., Jiang, S., Yang, X., Fan, C., Wang, H., Wang, J., Shi, Y. W.,
 Xiao, C., Zhong, M., & Yang, X. (2021). Distinct placental molecular processes associated with earlyonset and late-onset preeclampsia. *Theranostics*, *11*(10), 5028–5044.
- 583 https://doi.org/10.7150/thno.56141
- Rumer, K. K., Uyenishi, J., Hoffman, M. C., Fisher, B. M., & Winn, V. D. (2013). Siglec-6 expression is
 increased in placentas from pregnancies complicated by preterm preeclampsia. *Reproductive Sciences*. https://doi.org/10.1177/1933719112461185
- Singh, H., Zhao, M., Chen, Q., Wang, Y., Li, Y., Kaitu'U-Lino, T. J., Tong, S., & Nie, G. (2015). Human HtrA4
 expression is restricted to the placenta, is significantly Up-regulated in early-onset preeclampsia,
 and high levels of HtrA4 cause endothelial dysfunction. *Journal of Clinical Endocrinology and Metabolism*, 33(4), 5058–5066. https://doi.org/10.1210/jc.2014-3969
- Taylor, B. D., Ness, R. B., Olsen, J., Hougaard, D. M., Skogstrand, K., Roberts, J. M., & Haggerty, C. L.
 (2015). Serum leptin measured in early pregnancy is higher in women with preeclampsia compared
 with normotensive pregnant women. *Hypertension*, 65(3), 594–599.
 https://doi.org/10.1161/HYPERTENSIONAHA.114.03979
- Tejera, E., Bernardes, J., & Rebelo, I. (2013). Co-expression network analysis and genetic algorithms for
 gene prioritization in preeclampsia. *BMC Medical Genomics*, 6(51), 1–10.
 https://doi.org/10.1186/1755-8794-6-51
- Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A.,
 Arab, T., Archer, F., Atkin-Smith, G. K., Ayre, D. C., Bach, J. M., Bachurski, D., Baharvand, H., Balaj,
 L., Baldacchino, S., Bauer, N. N., Baxter, A. A., Bebawy, M., ... Zuba-Surma, E. K. (2018). Minimal
 information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the
 International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *Journal of Extracellular Vesicles*, 7(1), 1–43. https://doi.org/10.1080/20013078.2018.1535750
- Tsai, S., Hardison, N. E., James, A. H., Motsinger-Reif, A. A., Bischoff, S. R., Thames, B. H., & Piedrahita, J.
 A. (2011a). Transcriptional profiling of human placentas from pregnancies complicated by

606 607	preeclampsia reveals disregulation of sialic acid acetylesterase and immune signalling pathways. <i>Placenta, 32</i> (2), 175–182. https://doi.org/10.1016/j.placenta.2010.11.014
608 609 610 611	 Tsai, S., Hardison, N. E., James, A. H., Motsinger-Reif, A. A., Bischoff, S. R., Thames, B. H., & Piedrahita, J. A. (2011b). Transcriptional profiling of human placentas from pregnancies complicated by preeclampsia reveals disregulation of sialic acid acetylesterase and immune signalling pathways. <i>Placenta</i>, <i>32</i>(2), 175–182. https://doi.org/10.1016/j.placenta.2010.11.014
612 613 614 615	 Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., Sanli, K., Von Feilitzen, K., Oksvold, P., Lundberg, E., Hober, S., Nilsson, P., Mattsson, J., Schwenk, J. M., Brunnström, H., Ponten, F. (2017). A pathology atlas of the human cancer transcriptome. <i>Science</i>, <i>357</i>(6352). https://doi.org/10.1126/science.aan2507
616 617 618	Wang, Y., Lim, R., & Nie, G. (2019). HtrA4 may play a major role in inhibiting endothelial repair in pregnancy complication preeclampsia. <i>Scientific Reports, 9</i> (1), 1–14. https://doi.org/10.1038/s41598-019-39565-9
619 620 621	Wei, J., Fu, Y., Mao, X., Jing, Y., Guo, J., & Ye, Y. (2019). Decreased Filamin b expression regulates trophoblastic cells invasion through ERK/MMP-9 pathway in pre-eclampsia. <i>Ginekologia Polska</i> , 90(1), 39–45. https://doi.org/10.5603/GP.2019.0006
622 623	Weissgerber, T. L., & Mudd, L. M. (2015). Preeclampsia and Diabetes. In <i>Current Diabetes Reports</i> (Vol. 15, Issue 3). https://doi.org/10.1007/s11892-015-0579-4
624 625 626	Xie, J., Xu, Y., Wan, L., Wang, P., Wang, M., & Dong, M. (2018). Involvement of follistatin-like 3 in preeclampsia. <i>Biochemical and Biophysical Research Communications</i> , 506(3):692-697(3), 692–607. https://doi.org/10.1016/j.bbrc.2018.10.139
627 628 629 630 631	 Yáñez-Mó, M., Siljander, P. R. M., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., Colás, E., Cordeiro-Da Silva, A., Fais, S., Falcon-Perez, J. M., Ghobrial, I. M., Giebel, B., Gimona, M., Graner, M., Gursel, I., De Wever, O. (2015). Biological properties of extracellular vesicles and their physiological functions. <i>Journal of Extracellular Vesicles</i>, 4(1), 1–60. https://doi.org/10.3402/jev.v4.27066
632 633 634	Zhang, M., Angata, T., Cho, J. Y., Miller, M., Broide, D. H., & Varki, A. (2007). Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. <i>Blood</i> , <i>109</i> (10), 4280–4287. https://doi.org/10.1182/blood-2006-08-039255
635	

- - -

636

637

639

641	Supp	lementary	Material
-----	------	-----------	----------

- 642 Supplemental Methods
- 643 Table S1-S4
- 644 Figure S1-S4
- 645 List of differentially abundant mRNA and functional enrichment analysis:
- 646 DOI: 10.17632/6s5fkd3z7t.1

657		
658		
659		
660		
661		
662		
663		
664		
665		
666		
667	Supplemental Material	
668		
669		
670		
671		
672		
673		
674		

675

676

677 Supplemental Methods

678 Enrichment of STB-EVs by placental dual-lobe perfusion and serial ultracentrifugation

679 Briefly, we identified a suitable cotyledon (devoid of calcifications, ischemia, or rupture) and cannulated a placental artery and vein perfusing the placenta for three hours at a 4-5 ml/min flow 680 rate to obtain placenta perfusate. The placenta perfusate was centrifuged twice at 1,500 g for ten 681 minutes at 4°C (Beckman Coulter Avanti J-20XP centrifuge using a Beckman Coulter JS-5.3 682 swing-out rotor) to remove cell debris. The supernatant was carefully pooled and spun at 10,000 683 g (10K) in a swing bucket centrifuge (Beckman L80 ultracentrifuge and Sorvall TST28.39 swing-684 *out rotor*) at 4⁰C for 30 minutes. The 10K STB-EV pellet was washed with filtered phosphate 685 buffer saline (fPBS) followed by resuspension of the 10K STB-EV pellets in fPBS. An aliquot of 686 687 the resuspended pellets was analysed to identify and characterise STB-EVs, while the rest were aliquoted to obtain a protein concentration around 2-5 µg/µl (measured using a Pierce 688 bicinchoninic acid (BCA) protein assay) and immediately stored at -80°C. The post-10K 689 690 supernatant was filtered through a 0.22 µm Millipore stericup filtration device, then spun at 150,000 g for 2 hours (Beckman L80 ultracentrifuge with a Sorvall TST28.39 swing-out rotor) 691 692 and the 150K STB-EV pellets were washed, resuspended in fPBS and aliquoted like the 10K STB-EV pellets. This working stock was used for subsequent analysis. 693

694 Transmission electron microscopy

695 STB-EV pellets were diluted with fPBS to achieve an STB-EV solution with concentrations 696 between 0.1-0.3 μ g/ μ l. Ten microliter of the STB-EV pellet solution was applied to freshly

697 glowing discharged carbon formvar 300 mesh copper grids for two minutes, blotted with filter 698 paper, and stained with 2% uranyl acetate for ten seconds and air-dried. STB-EV pellets on the 699 grid were negatively stained to enhance the contrast between STB-EVs pellets and the 690 background. The grids were imaged using an FEI Tecnai 12 TEM at 120 kV with a Gatan 691 OneView CMOS camera.

702 Flow Cytometry

A BD LSRII flow cytometer (BD Biosciences) with a blue, violet, and red laser was used for all 703 sample analyses. Daily quality control (QC) was run using CS&T beads (BD Biosciences). 704 Photomultiplier tube (PMT) voltage determined by CS&T run was applied to all fluorescent 705 detectors with exception for the side scatter (SSC) which was determined by Apogee Mix (1493, 706 Apogee Flow System, UK). SSC PMT voltage that triggered 0.59 µm silica beads and above was 707 applied to all 10K STB-EV pellets and analyzed. An SSC threshold of 200 was applied to 708 remove background noise below 0.59 µm silica beads. A flow rate of 10 µl/min was achieved 709 710 using the TruCount beads (BD science). For sample staining, 90 ml of 10K STB-EV pellet were incubated with ten ml of Fc receptor blocker (Miltenyl, UK) for 10 minutes at 4°C and then 711 stained with phycoerythrin (PE) conjugated PLAP (for syncytiotrophoblast origin), PE Vio770 712 conjugated anti classical HLA class I and II (to exclude co-isolated non-placenta EVs and white 713 blood cell (WBC) EV co-isolation), Pacific blue conjugated CD41 (to identify co-isolated 714 platelet EVs) and CD235a (to identify co-isolated red blood cell (RBC) EVs) for ten minutes at 715 room temperature in the dark. Stained samples were transferred to an Ultra free 0.2 µm filter unit 716 (Millipore) and centrifuged at 800 g for three minutes to remove unbound antibodies and EVs 717 718 smaller than the filter pore size. Ninety microliters of fPBS were used to recover 10K STB-EVs 719 retained on the filter membrane. Recovered 10K STB-EVs were further stained with BODIPY

720	FL N-(2-aminoethyl)-maleimide [505/513 nm] (Molecular Probes) at a final concentration of 0.5
721	nM in the dark at room temperature for ten minutes before samples were diluted to 500 ml and
722	analyzed on the flow cytometer to check for events rate. When necessary, dilutions were made to
723	achieve an events rate of \leq 400 count/second and to reduce swarming. 10K STB-EV pellets were
724	analyzed at 10 μ l/minute for ten minutes and a total of 100 μ l diluted samples was analyzed for
725	each sample. Fluorescence minus one (FMO-1) for each fluorochrome and stained samples re-
726	acquired after 2% Nonidet P-40 (NP-40) (Sigma) treatment were used as controls. Data and
727	figures generated were generated with the Flowjo software version 10 (Tree Star Inc., Ashland,
728	OR).
729	
730	
731	
732	
733	
734	
705	
/35	
736	
737	
738	
739	

740

741

742 Flow Cytometry



analysis of m/lSTB-EVs Figure S1. Representative flow enriched by placental 744 perfusion. Apogee beads mix was used to set the flow machine's light scatter resolution to 0.59-745 746 1.3 mm silica beads (Figure S1A); Application of SSC and FSC PMTVs determined by apogee beads mix for the analysis of M/L STB-EVs (Figure S1B). An investigation gate interrogating 747 m/l STB- EVs which did not express the non-placental markers HLA Class 1 & II, CD41a and 748 749 CD235a - thus removing co-isolated non-placental EVs (Figure S1C). STB-EVs from the 750 investigation gate were further analyzed for expression of PLAP and staining by bioM- which

stains proteins (Figure S1D). This revealed a high number (95%) of PLAP positive vesicles.
These PLAP+ bioM+ double positive EVs were highly sensitive to detergent treatment (Panel E)
with the reduction in PLAP+ bioM+ double positivity confirming that they are vesicular in
nature.

755



Figure S2. Reagent controls, 0.1mm filtered PBS (A); 0.2mm filtered bioM (B) and antibody
cocktail (C) all showing no PLAP+ bioM+ double positivity. Fluorescent minus one (FMO-1)
controls, bioM-1 control (D); PE Vio770-1 control (E); PE-1 control (F).

760

756

762

763

764 Nanoparticle Tracking Analysis

We further characterised the 10K and 150K STB-EV pellets by nanoparticle tracking analysis 765 766 [(NTA) NanoSight NS500 instrument equipped with a 405 nm laser (Malvern UK), sCMOS 767 camera and NTA software version 2.3, Build 0033 (Malvern UK)]. Before sample analysis, 768 instrument performance was checked with silica 100 nm microspheres (Polysciences, Inc.). The 769 10K and 150K STB-EV pellets were individually diluted in fPBS to a range of 1/100,000. The 770 samples were automatically injected into the sample chamber with a 1 ml syringe with the 771 following script used for EV measurements: prime, delay 5, capture 60, repeat 4. Images of the 772 analyzed samples were captured on camera at level 12 (Camera shutter speed; 15 milliseconds and Camera gain; 350) and NTA post-acquisition settings were optimized and kept constant 773 between samples. Each video recording was analyzed to infer STB-EVs size and concentration 774 profile. 775

776 Western Blot Analysis

We performed western blots on placental lysates (PL) and STB-EVs to further characterise and immune-phenotype. All STB-EVs pellets were probed with PLAP (for syncytiotrophoblast origin), CD63 and ALIX (to confirm the presence of extracellular vesicles), and Cytochrome C (as a negative EV marker) as recommended by the international society for extracellular vesicles (ISEV) (Théry et al., 2018). Following characterization and identification of extracellular vesicles in 10K and 150K STB-EV pellets, we renamed them to medium/large (m/l) and small (s) STB-EVs respectively.

784	
-----	--

785

786

Table S1. Table showing the antibodies used for Western blot.

Antibodies	Concentration	Dilution	Antigen	Specificity	Manufac	turer
Anti-PLAP					In	house
(NDOG 2)	1.6 µg/µl	1/1000	PLAP	STB-EV	antibody	
					Santa	Cruz
Anti-CD63	200 µg/µl	1/1000	CD63	STB-EV	Biotechn	ology
Anti-ALIX	200 µg/µl	1/1000	ALIX	S STB-EV	Cell Sign	alling
Anti-						
Cytochrom			Cytochro	Placenta	Santa	Cruz
e C	200 µg/µl	1/500	me C	homogenate	Biotechn	ology
			Mouse			
			and			
Polyclonal	goat-anti-		Rabbit			
mouse/rabbit	-		Immunogl			
immunoglobulin HRP 1/2		1/2000	obulins	N/A	Dako UK	Ltd

788

789

790 RNA-Sequencing Library Preparation and Sequencing

For placental biopsy, 30 milligrams of placenta tissue were mechanically homogenized, and the RNA extracted with the RNeasy kit. An equal amount of STB-EV (200 μ g) was diluted up to 200 μ l. Total RNA was then extracted from this STB-EV mixture with the miRCURYTM RNA isolation kit. The extracted RNA was assessed for purity with Nanodrop (NanoDrop 1000 Software). After confirming that all samples had a 260/280 ratio greater than 1.8, the samples were sent to the Wellcome Centre for Human Genetics (WCHG) for sequencing. At WCHG, the RNA was assessed with a Bioanalyzer (Agilent Technologies) to determine the concentration

and RIN values (for PL) which were all greater than 8 except the STB-EV samples with RIN
between 1-3. It is widely accepted that the RIN values are not applicable for extracellular
vesicles due to 1) the fragmented nature of RNA they contain and the limited presence of 18S
and 28S ribosomal RNA peaks.

802 RNA libraries were prepared using the TruSeq RNA library preparation and small RNA library 803 preparation kits (Illumina). A standard procedure was followed for mRNA sequencing. Briefly, 804 polyadenylated mRNAs were selected from total RNA samples using oligo-dT-conjugated magnetic beads. Poly-adenylated RNA samples were immediately converted into stranded 805 806 Illumina sequencing libraries using 200 bp fragmentation and sequential adapter following the manufacturer's specifications. The resulting cDNA was amplified, enriched, and indexed using 807 12 cycles of amplification with PCR primers, including an index sequence to allow for 808 809 multiplexing. All RNA sequences were purified on gels and sequenced on a HiSeq2500 high output v3 flow cell using paired-end, 75 bp reads (Illumina). 810

- 811
- 812
- 813
- 814
- 815
- 816
- 817

819			
820			

821

822 Taqman Gene expression assays

Table S2. Table showing qPCR Primers, assay ID and amplicon length.

Gene Symbol	Assay ID	Amplicon Length
PAPP-A2	Hs00535718_m1	67
INHBA	Hs01081598_m1	61
SIGLEC6	Hs00971272_g1	117
HTRA4	Hs00538137_m1	75
EB13	Hs01057148_m1	64
FSTL3	Hs00610505_m1	84
HSD17B1	Hs00166219_g1	124
CGB3	Hs00361224_gh	55
YWHAZ	Hs01122445_g1	62
LEP	Hs00174877_m1	74
COL17A1	Hs00990036_m1	57
FLNB	Hs00963202_m1	100
SLC45A4	Hs01088148_m1	70

824

826			
827			
828			

829 Supplementary results

Table S3. General characteristics of the STB-EV qPCR validation study population

Characteristics	Normal Pregnancy	Preeclampsia	P Value	
Sample size	6	6		
Maternal age years (mean (SD))	35.50 (4.80)	37.25 (4.11)	0.600	
Body mass index kg/m ⁻² (mean				
(SD))	24.25(3.30)	34.88 (12.28)	0.146	
Systolic blood pressure mmHg				
(mean (SD))	109.50 (6.86)	183.75 (12.87)	<0.001	
Diastolic blood pressure mmHg				
(mean (SD))	76.00 (1.41)	113.25 (9.71)	<0.001	
Proteinuria plus(es) (mean				
(SD))	0	3.00 (0.82)	<0.001	
Gestational age at delivery in				
weeks (mean (SD))	39.50 (0.58)	33.50 (3.00)	0.008	
Birth weight (grams) (mean				
(SD))	3627.50(247.98)	1808.75(488.54)	0.001	
Intrauterine growth restriction				
(IUGR) = Yes (%) ⁻	0 (0)	4(100.00)	0.034	
Male new-born gender (%)	2 (50.00)	1 (25.00)	1.000	



833

Figure S3. Volcano plot showing differentially expressed genes in the placenta. The most
significantly upregulated genes are displayed in red on the right while the most significantly
downregulated genes are displayed in red on the left.

837



Figure S4. Volcano plot showing differentially carried genes in small STB-EVs. The most
significantly upregulated genes are displayed in red on the right while the most significantly
downregulated genes are displayed in red on the left.

851 Table S4. List of overlapping gene ontology (GO) terms and KEGG Pathways in the placenta,

852 medium/large STB-EVs and small STB-EVs

Sample Type	Gene Ontology terms and KEGG Pathway(s)
Biological Process (BP)	
Placenta and sSTB-EVs	Extracellular matrix organization
	Extracellular structure organization
	Cell-substrate adhesion
	Regulation of vasculature development
	Regulation of cell-substrate adhesion
	Positive regulation of vasculature development
	Cell-substrate junction assembly
	Cell-matrix adhesion
	Cell-substrate junction organization
	Positive regulation of angiogenesis
	Regulation of cell-matrix adhesion
	Positive regulation of cell adhesion
	Regulation of cellular response to growth factor stimulus
	Negative regulation of locomotion
	Endocrine process
	Negative regulation of cell-matrix adhesion
	Regulation of endocrine process
	Transmembrane receptor protein serine/threonine kinase signalling pathway
	Positive regulation of phosphatidylinositol 3-kinase signalling
	Regulation of transmembrane receptor protein serine/threonine kinase
	signalling pathway
	Endocrine hormone secretion
	Response to transforming growth factor beta
	Cellular response to transforming growth factor beta stimulus
	Response to decreased oxygen levels.
	Negative regulation of myeloid leukocyte differentiation
	Regulation of phosphatidylinositol 3-kinase signalling
	Response to hypoxia
	Response to oxygen levels
	1 58
	Maintenance of location
	Regulation of gonadotropin secretion
	NAD metabolic process
	Lipid localization
Placenta and m/ISTB-EVs	Platelet degranulation
Molecular Function (MF)	
Placenta and sSTB-EVs	Cell adhesion molecule binding,
	Integrin binding
Cellular Component (CC)	
Placenta and sSTB-EVs	Collagen-containing extracellular matrix
	Leading-edge membrane
	Ruffle membrane
	Cell-cell junction
m/lSTB-EVs and sSTB-EVs	Vesicle lumen
Placenta, m/l STB-EVs and sSTB-EVs	Actin cytoskeleton
	Cytoplasmic vesicle lumen
	Secretory granule lumen
	Focal adhesion
	Cell-substrate junction
	ن د

		Contractile fibre
	Placenta and m/ISTB-EVs	Platelet alpha granule lumen
	REGG Pathways	ECM resenter internation
	Flacenta and SSTB-EVS	Inflammatory mediator regulation of TRP channels
		HIF-1 signalling nathway
		Glycolysis/gluconeogenesis
		Central carbon metabolism in cancer
		Proteoglycans in cancer
	Placenta, m/ISTB-EVs and sSTB-EVs	Focal adhesion
853		
854		
855		
856		
057		
857		
0 - 0		
020		
850		
055		
860		
000		
861		
862		
863		
864		
865		
866		
0.07		
80/		